Literature DB >> 26072408

STAT3 Decoy ODN Therapy for Cancer.

Xiaoxia Sun1, Jian Zhang.   

Abstract

As an oncogene, over-activated signal transducer and activator of transcription 3 (STAT3) has been detected in many tumors. STAT3 controls cell differentiation, proliferation, and survival, and is associated with angiogenesis and immune dysfunction during tumorigenesis. Double-stranded decoy oligodeoxynucleotide (ODN) targeting over-activated STAT3 in tumor cells have shown significant antitumor efficiency. Here, we describe the materials and methods involved in STAT3 decoy ODN therapy for cancer including both the antitumor effect directly and immunotherapy indirectly.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26072408     DOI: 10.1007/978-1-4939-2727-2_11

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  5 in total

1.  Nucleic Acid Targeted Therapy: G4 Oligonucleotides Downregulate HRAS in Bladder Cancer Cells through a Decoy Mechanism.

Authors:  Giulia Miglietta; Alaa S Gouda; Susanna Cogoi; Erik B Pedersen; Luigi E Xodo
Journal:  ACS Med Chem Lett       Date:  2015-10-18       Impact factor: 4.345

2.  A Brief Introduction to Current Cancer Gene Therapy.

Authors:  Dennis Kobelt; Jessica Pahle; Wolfgang Walther
Journal:  Methods Mol Biol       Date:  2022

3.  miR-1181 inhibits invasion and proliferation via STAT3 in pancreatic cancer.

Authors:  Jie Wang; Xing-Jun Guo; You-Ming Ding; Jian-Xin Jiang
Journal:  World J Gastroenterol       Date:  2017-03-07       Impact factor: 5.742

Review 4.  Manipulation of JAK/STAT Signalling by High-Risk HPVs: Potential Therapeutic Targets for HPV-Associated Malignancies.

Authors:  Ethan L Morgan; Andrew Macdonald
Journal:  Viruses       Date:  2020-09-03       Impact factor: 5.048

5.  MicroRNA-411 Inhibits Cervical Cancer Progression by Directly Targeting STAT3.

Authors:  Dan Shan; Yumin Shang; Tongxiu Hu
Journal:  Oncol Res       Date:  2018-05-01       Impact factor: 5.574

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.